Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance
- PMID: 8275942
- DOI: 10.1210/endo.134.1.8275942
Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance
Abstract
As obesity is a major risk factor for noninsulin-dependent diabetes mellitus, adipose tissue may generate a mediator that influences the activity of insulin on various _target tissues. Recent evidence suggests that a cytokine, tumor necrosis factor-alpha (TNF alpha), may serve this role. This study investigates whether the expression of TNF alpha and its receptors is modulated during drug treatment to reduce insulin resistance. The effects of moderate weight loss by dietary restriction were also examined. We show here that a marked induction of TNF alpha mRNA occurs in adipose tissues from a mouse model of obesity-linked diabetes (KKAy) compared to that in nondiabetic mice (C57). Likewise, RNA transcripts encoding TNF R2 receptors (p75) were significantly increased in fat tissues of the obese diabetic animals. In muscle from these diabetic animals, RNA transcripts encoding both TNF R1 (p55) and R2 were significantly elevated, although R2 transcript abundance was less elevated than in fat. We also observed that the overexpression of mRNA for TNF alpha and both of its receptors could be at least partly normalized by treatment of the diabetic animals with the insulin-sensitizing agent pioglitazone. Treating of the obese diabetic animals by food restriction reduced the expression of mRNA for TNF R2 in muscle, but not fat. These results clearly indicate that gene expression for the TNF systems can be regulated by an insulin-sensitizing drug and reduction of body weight. Such findings support a role for this cytokine in the insulin-resistant diabetic state and show its modulation by therapies that reverse the disorder.
Similar articles
-
Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus.Eur J Clin Invest. 1999 Aug;29(8):672-8. doi: 10.1046/j.1365-2362.1999.00520.x. Eur J Clin Invest. 1999. PMID: 10457150
-
Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.Endocrinology. 1992 Feb;130(2):735-40. doi: 10.1210/endo.130.2.1733721. Endocrinology. 1992. PMID: 1733721
-
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.Diabetes. 1999 Sep;48(9):1830-5. doi: 10.2337/diabetes.48.9.1830. Diabetes. 1999. PMID: 10480615
-
Mechanisms of TNF-alpha-induced insulin resistance.Exp Clin Endocrinol Diabetes. 1999;107(2):119-25. doi: 10.1055/s-0029-1212086. Exp Clin Endocrinol Diabetes. 1999. PMID: 10320052 Review.
-
[Obesity, insulin resistance and the implication of thiazolidinediones].Nihon Rinsho. 2000 Feb;58(2):411-5. Nihon Rinsho. 2000. PMID: 10707567 Review. Japanese.
Cited by
-
The role of TNF-alpha in insulin resistance.Endocrine. 2004 Mar-Apr;23(2-3):177-82. doi: 10.1385/ENDO:23:2-3:177. Endocrine. 2004. PMID: 15146098 Review.
-
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.World J Gastroenterol. 2008 Jan 7;14(1):22-8. doi: 10.3748/wjg.14.22. World J Gastroenterol. 2008. PMID: 18176957 Free PMC article. Review.
-
Ceramides as modulators of cellular and whole-body metabolism.J Clin Invest. 2011 Nov;121(11):4222-30. doi: 10.1172/JCI57144. Epub 2011 Nov 1. J Clin Invest. 2011. PMID: 22045572 Free PMC article. Review.
-
Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.J Clin Invest. 1994 Oct;94(4):1543-9. doi: 10.1172/JCI117495. J Clin Invest. 1994. PMID: 7523453 Free PMC article.
-
Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives.Vasc Health Risk Manag. 2008;4(2):297-304. doi: 10.2147/vhrm.s993. Vasc Health Risk Manag. 2008. PMID: 18561505 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials